Research programme: protein kinase inhibitors - SignalChem Lifesciences

Drug Profile

Research programme: protein kinase inhibitors - SignalChem Lifesciences

Alternative Names: AXL inhibitors - SignalChem Lifesciences; CAIX inhibitors - SignalChem Lifesciences; MELK inhibitors - SignalChem Lifesciences; PKD2 inhibitors - SignalChem Lifesciences; SLC 0211; SLC-0121; SLC-0131; SLC-391; TYRO3 inhibitors - SignalChem Lifesciences

Latest Information Update: 25 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator SignalChem Lifesciences
  • Class Anti-inflammatories; Antibodies; Antineoplastics; Small molecules
  • Mechanism of Action Axl receptor tyrosine kinase inhibitors; Carbonic anhydrase inhibitors; Interleukin-1 receptor-associated kinase inhibitors; LRRK2 protein inhibitors; MELK protein inhibitors; NF-kappa B inhibitors; Polycystic kidney disease 2 protein inhibitors; Protein kinase inhibitors; Proto-oncogene protein c-mer inhibitors; Tau tubulin kinase 1 inhibitors; TYRO3 receptor protein tyrosine kinase antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer
  • Research Alzheimer's disease; Autoimmune disorders; Inflammation; Parkinson's disease
  • No development reported Breast cancer

Most Recent Events

  • 17 Jul 2017 SignalChem LifeSciences plans a phase I trial for SLC 0211 for Cancer in the second quarter of 2017 (SignalChem LifeSciences website, July 2017)
  • 01 Apr 2017 Protein kinase inhibitors - SignalChem Lifescience is still in preclinical development for Cancer in Canada
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Breast-cancer in Canada
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top